Cargando…

Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

BACKGROUND: Aldosterone is elevated in chronic kidney disease (CKD) and may be involved in hypertension. Surprisingly, the determinants of the plasma aldosterone concentration (PAC) and its role in hypertension are not well studied in CKD. Therefore, we studied the determinants of aldosterone and it...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gant, Christina M., Laverman, Gozewijn D., Vogt, Liffert, Slagman, Maartje C. J., Heerspink, Hiddo J. L., Waanders, Femke, Hemmelder, Marc H., Navis, Gerjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738866/ https://www.ncbi.nlm.nih.gov/pubmed/29262813 http://dx.doi.org/10.1186/s12882-017-0789-x

Ejemplares similares

Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial
por: Slagman, Maartje C J, et al.
Publicado: (2011)

Higher Dietary Magnesium Intake and Higher Magnesium Status Are Associated with Lower Prevalence of Coronary Heart Disease in Patients with Type 2 Diabetes
por: Gant, Christina M., et al.
Publicado: (2018)

Indomethacin Reduces Glomerular and Tubular Damage Markers but Not Renal Inflammation in Chronic Kidney Disease Patients: A Post-Hoc Analysis
por: de Borst, Martin H., et al.
Publicado: (2012)

Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD
por: Wouda, Rosa D, et al.
Publicado: (2021)

Improvement of Sodium Status to Optimize the Efficacy of Renin-Angiotensin System Blockade
por: Laverman, Gozewijn D., et al.
Publicado: (2011)

The renoprotective effects of sulodexide
por: Olde Engberink, Rik HG, et al.
Publicado: (2016)

Integrated Assessment of Pharmacological and Nutritional Cardiovascular Risk Management: Blood Pressure Control in the DIAbetes and LifEstyle Cohort Twente (DIALECT)
por: Gant, Christina M., et al.
Publicado: (2017)

Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT)
por: Beernink, Jelle M., et al.
Publicado: (2022)

Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors
por: Gant, Christina M., et al.
Publicado: (2018)

Glycaemic control in the diabetes and Lifestyle Cohort Twente: A cross‐sectional assessment of lifestyle and pharmacological management on Hba1c target achievement
por: Jalving, Annis C., et al.
Publicado: (2018)

Personalized Nutrition in Patients with Type 2 Diabetes and Chronic Kidney Disease: The Two-Edged Sword of Dietary Protein Intake
por: Oosterwijk, Milou M., et al.
Publicado: (2022)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

Body weight course in the DIAbetes and LifEstyle Cohort Twente (DIALECT-1)—A 20-year observational study
por: Gant, Christina M., et al.
Publicado: (2019)

Synergic Renoprotective Effects of Combined ASC Therapy with RAAS Blockade in Experimental Advanced CKD
por: Maires, Marina P. C., et al.
Publicado: (2022)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

High Dietary Intake of Vegetable Protein Is Associated With Lower Prevalence of Renal Function Impairment: Results of the Dutch DIALECT-1 Cohort
por: Oosterwijk, Milou M., et al.
Publicado: (2019)

Lower Renal Function Is Associated With Derangement of 11-β Hydroxysteroid Dehydrogenase in Type 2 Diabetes
por: Gant, Christina Maria, et al.
Publicado: (2018)

Lifestyle-Related Exposure to Cadmium and Lead is Associated with Diabetic Kidney Disease
por: Hagedoorn, Ilse J. M., et al.
Publicado: (2020)

Determinants of Increased Serum Calprotectin in Patients with Type 2 Diabetes Mellitus
por: Oosterwijk, Milou M., et al.
Publicado: (2020)

Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial
por: Kwakernaak, A. J., et al.
Publicado: (2017)

Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real life population of complicated type 2 diabetes – contraindications and opportunities
por: Gant, C. M., et al.
Publicado: (2023)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
por: Kroonen, Marjolein Y. A. M., et al.
Publicado: (2020)

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies
por: Olde Engberink, Rik H. G., et al.
Publicado: (2016)

SUN-LB98 RAAS Triple-A Analysis for the Screening of Primary Aldosteronism
por: Burrello, Jacopo, et al.
Publicado: (2020)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores
por: Idzerda, Nienke M. A., et al.
Publicado: (2021)

Clinical and Dietary Determinants of Muscle Mass in Patients with Type 2 Diabetes: Data from the Diabetes and Lifestyle Cohort Twente
por: Jalving, Annis C., et al.
Publicado: (2021)

Urinary Vitamin D Binding Protein: A Potential Novel Marker of Renal Interstitial Inflammation and Fibrosis
por: Mirković, Katarina, et al.
Publicado: (2013)

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017)

Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
por: Gnudi, Luigi, et al.
Publicado: (2010)

Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction
por: Farhadi, Susan A. S., et al.
Publicado: (2019)

The renin-angiotensin-aldosterone system (RAAS) signaling pathways and cancer: foes versus allies
por: Hassani, Bahareh, et al.
Publicado: (2023)

Low Physical Activity in Patients with Complicated Type 2 Diabetes Mellitus Is Associated with Low Muscle Mass and Low Protein Intake
por: Hagedoorn, Ilse J. M., et al.
Publicado: (2020)

Why the renin–angiotensin–aldosterone system (RAAS) in critically ill patients can no longer be ignored
por: Zarbock, Alexander, et al.
Publicado: (2021)

Impact of Moderate Sodium Restriction and Hydrochlorothiazide on Iodine Excretion in Diabetic Kidney Disease: Data from a Randomized Cross-Over Trial
por: Binnenmars, S. Heleen, et al.
Publicado: (2019)

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis
por: Pirola, Carlos J., et al.
Publicado: (2020)

Different roles of the RAAS affect bone metabolism in patients with primary aldosteronism, Gitelman syndrome and Bartter syndrome
por: Tang, Wangna, et al.
Publicado: (2022)

An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers
por: Maideen, Naina Mohamed Pakkir, et al.
Publicado: (2022)

New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition
por: Fagyas, Miklós, et al.
Publicado: (2014)

Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats
por: Yuan, Yi-Ming, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qitlsbfo7enahsfml2qjp49ph3